Effectiveness and tolerability of second‐line therapy with vildagliptin vs. other oral agents in type 2 diabetes: A real‐life worldwide observational study (EDGE)
Identifieur interne : 000680 ( Main/Exploration ); précédent : 000679; suivant : 000681Effectiveness and tolerability of second‐line therapy with vildagliptin vs. other oral agents in type 2 diabetes: A real‐life worldwide observational study (EDGE)
Auteurs : C. Mathieu [Belgique] ; A. H. Barnett [Royaume-Uni] ; H. Brath [Autriche] ; I. Conget [Portugal] ; J. J. De Castro [Espagne] ; R. Göke [Allemagne] ; E. Márquez Rodriguez [Mexique] ; P. M. Nilsson [Suède] ; E. Pagkalos [Grèce] ; A. Penfornis [France] ; N. C. Schaper [Pays-Bas] ; S. K. Wangnoo [Inde] ; W. Kothny [États-Unis] ; G. Bader [Suisse]Source :
- International Journal of Clinical Practice [ 1368-5031 ] ; 2013-10.
Abstract
Real‐life studies are needed to confirm the clinical relevance of findings from randomised controlled trials (RCTs). This study aimed to assess the effectiveness and tolerability of vildagliptin add‐on vs. other oral antihyperglycaemic drugs (OADs) added to OAD monotherapy in a real‐life setting, and to explore the advantages and limitations of large‐scale ‘pragmatic’ trials.
Url:
DOI: 10.1111/ijcp.12252
Affiliations:
- Allemagne, Autriche, Belgique, Espagne, France, Grèce, Inde, Mexique, Pays-Bas, Portugal, Royaume-Uni, Suisse, Suède, États-Unis
- Angleterre, Catalogne, Midlands de l'Ouest, Vienne (Autriche)
- Barcelone, Birmingham, Vienne (Autriche)
- Université de Birmingham
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001260
- to stream Istex, to step Curation: 001236
- to stream Istex, to step Checkpoint: 000337
- to stream Main, to step Merge: 000681
- to stream Main, to step Curation: 000680
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effectiveness and tolerability of second‐line therapy with vildagliptin vs. other oral agents in type 2 diabetes: A real‐life worldwide observational study (EDGE)</title><author><name sortKey="Mathieu, C" sort="Mathieu, C" uniqKey="Mathieu C" first="C." last="Mathieu">C. Mathieu</name></author><author><name sortKey="Barnett, A H" sort="Barnett, A H" uniqKey="Barnett A" first="A. H." last="Barnett">A. H. Barnett</name></author><author><name sortKey="Brath, H" sort="Brath, H" uniqKey="Brath H" first="H." last="Brath">H. Brath</name></author><author><name sortKey="Conget, I" sort="Conget, I" uniqKey="Conget I" first="I." last="Conget">I. Conget</name></author><author><name sortKey="De Castro, J J" sort="De Castro, J J" uniqKey="De Castro J" first="J. J." last="De Castro">J. J. De Castro</name></author><author><name sortKey="Goke, R" sort="Goke, R" uniqKey="Goke R" first="R." last="Göke">R. Göke</name></author><author><name sortKey="Marquez Rodriguez, E" sort="Marquez Rodriguez, E" uniqKey="Marquez Rodriguez E" first="E." last="Márquez Rodriguez">E. Márquez Rodriguez</name></author><author><name sortKey="Nilsson, P M" sort="Nilsson, P M" uniqKey="Nilsson P" first="P. M." last="Nilsson">P. M. Nilsson</name></author><author><name sortKey="Pagkalos, E" sort="Pagkalos, E" uniqKey="Pagkalos E" first="E." last="Pagkalos">E. Pagkalos</name></author><author><name sortKey="Penfornis, A" sort="Penfornis, A" uniqKey="Penfornis A" first="A." last="Penfornis">A. Penfornis</name></author><author><name sortKey="Schaper, N C" sort="Schaper, N C" uniqKey="Schaper N" first="N. C." last="Schaper">N. C. Schaper</name></author><author><name sortKey="Wangnoo, S K" sort="Wangnoo, S K" uniqKey="Wangnoo S" first="S. K." last="Wangnoo">S. K. Wangnoo</name></author><author><name sortKey="Kothny, W" sort="Kothny, W" uniqKey="Kothny W" first="W." last="Kothny">W. Kothny</name></author><author><name sortKey="Bader, G" sort="Bader, G" uniqKey="Bader G" first="G." last="Bader">G. Bader</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B9764C37982951C07B33DEC4808354C963EDE84F</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1111/ijcp.12252</idno><idno type="url">https://api.istex.fr/document/B9764C37982951C07B33DEC4808354C963EDE84F/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001260</idno><idno type="wicri:Area/Istex/Curation">001236</idno><idno type="wicri:Area/Istex/Checkpoint">000337</idno><idno type="wicri:doubleKey">1368-5031:2013:Mathieu C:effectiveness:and:tolerability</idno><idno type="wicri:Area/Main/Merge">000681</idno><idno type="wicri:Area/Main/Curation">000680</idno><idno type="wicri:Area/Main/Exploration">000680</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effectiveness and tolerability of second‐line therapy with vildagliptin vs. other oral agents in type 2 diabetes: A real‐life worldwide observational study (EDGE)</title><author><name sortKey="Mathieu, C" sort="Mathieu, C" uniqKey="Mathieu C" first="C." last="Mathieu">C. Mathieu</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>I.G. – Endocrinologie, Campus Gasthuisberg, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation><affiliation></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Belgique</country></affiliation></author><author><name sortKey="Barnett, A H" sort="Barnett, A H" uniqKey="Barnett A" first="A. H." last="Barnett">A. H. Barnett</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Medicine, Diabetes Centre, Heart of England NHS Foundation Trust, University of Birmingham, Birmingham</wicri:regionArea><placeName><settlement type="city">Birmingham</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Midlands de l'Ouest</region></placeName><orgName type="university">Université de Birmingham</orgName></affiliation></author><author><name sortKey="Brath, H" sort="Brath, H" uniqKey="Brath H" first="H." last="Brath">H. Brath</name><affiliation wicri:level="3"><country xml:lang="fr">Autriche</country><wicri:regionArea>Health Center South, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Conget, I" sort="Conget, I" uniqKey="Conget I" first="I." last="Conget">I. Conget</name><affiliation wicri:level="1"><country xml:lang="fr">Portugal</country><wicri:regionArea>Department of Endocrinology & Diabetes, Armed Forces University Hospital, Lisboa</wicri:regionArea><wicri:noRegion>Lisboa</wicri:noRegion></affiliation></author><author><name sortKey="De Castro, J J" sort="De Castro, J J" uniqKey="De Castro J" first="J. J." last="De Castro">J. J. De Castro</name><affiliation wicri:level="3"><country xml:lang="fr">Espagne</country><wicri:regionArea>Diabetes Unit, Endocrinology and Nutrition Department, Hospital Clinic i Universitari, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Goke, R" sort="Goke, R" uniqKey="Goke R" first="R." last="Göke">R. Göke</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Innere Medizin, Schwerpkt Diabetologie, Kirchhain</wicri:regionArea><wicri:noRegion>Kirchhain</wicri:noRegion><wicri:noRegion>Kirchhain</wicri:noRegion></affiliation></author><author><name sortKey="Marquez Rodriguez, E" sort="Marquez Rodriguez, E" uniqKey="Marquez Rodriguez E" first="E." last="Márquez Rodriguez">E. Márquez Rodriguez</name><affiliation wicri:level="1"><country xml:lang="fr">Mexique</country><wicri:regionArea>Hospital Civil Viejo, Guadalajara</wicri:regionArea><wicri:noRegion>Guadalajara</wicri:noRegion></affiliation></author><author><name sortKey="Nilsson, P M" sort="Nilsson, P M" uniqKey="Nilsson P" first="P. M." last="Nilsson">P. M. Nilsson</name><affiliation wicri:level="1"><country xml:lang="fr">Suède</country><wicri:regionArea>Clinical research unit, Skåne University Hospital, Malmö</wicri:regionArea><wicri:noRegion>Malmö</wicri:noRegion></affiliation></author><author><name sortKey="Pagkalos, E" sort="Pagkalos, E" uniqKey="Pagkalos E" first="E." last="Pagkalos">E. Pagkalos</name><affiliation wicri:level="1"><country xml:lang="fr">Grèce</country><wicri:regionArea>Private Hospital “Thermi”, Thessaloniki</wicri:regionArea><wicri:noRegion>Thessaloniki</wicri:noRegion></affiliation></author><author><name sortKey="Penfornis, A" sort="Penfornis, A" uniqKey="Penfornis A" first="A." last="Penfornis">A. Penfornis</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Endocrinology‐Metabolism and Diabetology‐Nutrition, Jean Minjoz Hospital, University of Franche‐Comté, Besançon Cedex</wicri:regionArea><wicri:noRegion>Besançon Cedex</wicri:noRegion><wicri:noRegion>Besançon Cedex</wicri:noRegion></affiliation></author><author><name sortKey="Schaper, N C" sort="Schaper, N C" uniqKey="Schaper N" first="N. C." last="Schaper">N. C. Schaper</name><affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Division of Endocrinology, Department of Internal Medicine, University Hospital Maastricht, Maastricht</wicri:regionArea><wicri:noRegion>Maastricht</wicri:noRegion></affiliation></author><author><name sortKey="Wangnoo, S K" sort="Wangnoo, S K" uniqKey="Wangnoo S" first="S. K." last="Wangnoo">S. K. Wangnoo</name><affiliation wicri:level="1"><country xml:lang="fr">Inde</country><wicri:regionArea>Apollo Centre for Obesity, Diabetes & Endocrinology (ACODE), Indraprastha Apollo Hospital, New Delhi</wicri:regionArea><wicri:noRegion>New Delhi</wicri:noRegion></affiliation></author><author><name sortKey="Kothny, W" sort="Kothny, W" uniqKey="Kothny W" first="W." last="Kothny">W. Kothny</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, NJ, East Hanover</wicri:regionArea><wicri:noRegion>East Hanover</wicri:noRegion></affiliation></author><author><name sortKey="Bader, G" sort="Bader, G" uniqKey="Bader G" first="G." last="Bader">G. Bader</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Global Medical Affairs – Diabetes, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">International Journal of Clinical Practice</title><title level="j" type="abbrev">Int J Clin Pract</title><idno type="ISSN">1368-5031</idno><idno type="eISSN">1742-1241</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><date type="published" when="2013-10">2013-10</date><biblScope unit="volume">67</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="947">947</biblScope><biblScope unit="page" to="956">956</biblScope></imprint><idno type="ISSN">1368-5031</idno></series><idno type="istex">B9764C37982951C07B33DEC4808354C963EDE84F</idno><idno type="DOI">10.1111/ijcp.12252</idno><idno type="ArticleID">IJCP12252</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1368-5031</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Real‐life studies are needed to confirm the clinical relevance of findings from randomised controlled trials (RCTs). This study aimed to assess the effectiveness and tolerability of vildagliptin add‐on vs. other oral antihyperglycaemic drugs (OADs) added to OAD monotherapy in a real‐life setting, and to explore the advantages and limitations of large‐scale ‘pragmatic’ trials.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Autriche</li><li>Belgique</li><li>Espagne</li><li>France</li><li>Grèce</li><li>Inde</li><li>Mexique</li><li>Pays-Bas</li><li>Portugal</li><li>Royaume-Uni</li><li>Suisse</li><li>Suède</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Catalogne</li><li>Midlands de l'Ouest</li><li>Vienne (Autriche)</li></region><settlement><li>Barcelone</li><li>Birmingham</li><li>Vienne (Autriche)</li></settlement><orgName><li>Université de Birmingham</li></orgName></list><tree><country name="Belgique"><noRegion><name sortKey="Mathieu, C" sort="Mathieu, C" uniqKey="Mathieu C" first="C." last="Mathieu">C. Mathieu</name></noRegion><name sortKey="Mathieu, C" sort="Mathieu, C" uniqKey="Mathieu C" first="C." last="Mathieu">C. Mathieu</name></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Barnett, A H" sort="Barnett, A H" uniqKey="Barnett A" first="A. H." last="Barnett">A. H. Barnett</name></region></country><country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Brath, H" sort="Brath, H" uniqKey="Brath H" first="H." last="Brath">H. Brath</name></region></country><country name="Portugal"><noRegion><name sortKey="Conget, I" sort="Conget, I" uniqKey="Conget I" first="I." last="Conget">I. Conget</name></noRegion></country><country name="Espagne"><region name="Catalogne"><name sortKey="De Castro, J J" sort="De Castro, J J" uniqKey="De Castro J" first="J. J." last="De Castro">J. J. De Castro</name></region></country><country name="Allemagne"><noRegion><name sortKey="Goke, R" sort="Goke, R" uniqKey="Goke R" first="R." last="Göke">R. Göke</name></noRegion></country><country name="Mexique"><noRegion><name sortKey="Marquez Rodriguez, E" sort="Marquez Rodriguez, E" uniqKey="Marquez Rodriguez E" first="E." last="Márquez Rodriguez">E. Márquez Rodriguez</name></noRegion></country><country name="Suède"><noRegion><name sortKey="Nilsson, P M" sort="Nilsson, P M" uniqKey="Nilsson P" first="P. M." last="Nilsson">P. M. Nilsson</name></noRegion></country><country name="Grèce"><noRegion><name sortKey="Pagkalos, E" sort="Pagkalos, E" uniqKey="Pagkalos E" first="E." last="Pagkalos">E. Pagkalos</name></noRegion></country><country name="France"><noRegion><name sortKey="Penfornis, A" sort="Penfornis, A" uniqKey="Penfornis A" first="A." last="Penfornis">A. Penfornis</name></noRegion></country><country name="Pays-Bas"><noRegion><name sortKey="Schaper, N C" sort="Schaper, N C" uniqKey="Schaper N" first="N. C." last="Schaper">N. C. Schaper</name></noRegion></country><country name="Inde"><noRegion><name sortKey="Wangnoo, S K" sort="Wangnoo, S K" uniqKey="Wangnoo S" first="S. K." last="Wangnoo">S. K. Wangnoo</name></noRegion></country><country name="États-Unis"><noRegion><name sortKey="Kothny, W" sort="Kothny, W" uniqKey="Kothny W" first="W." last="Kothny">W. Kothny</name></noRegion></country><country name="Suisse"><noRegion><name sortKey="Bader, G" sort="Bader, G" uniqKey="Bader G" first="G." last="Bader">G. Bader</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Belgique/explor/OpenAccessBelV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000680 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000680 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Belgique
|area= OpenAccessBelV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:B9764C37982951C07B33DEC4808354C963EDE84F
|texte= Effectiveness and tolerability of second‐line therapy with vildagliptin vs. other oral agents in type 2 diabetes: A real‐life worldwide observational study (EDGE)
}}
| This area was generated with Dilib version V0.6.25. |  |